Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA.
Department of Nutrition Services, Dana Farber Cancer Institute, Boston, MA, USA.
J Geriatr Oncol. 2022 Jul;13(6):778-783. doi: 10.1016/j.jgo.2022.02.007. Epub 2022 Feb 25.
Polypharmacy is characterized by the simultaneous use of multiple medications, including prescription drugs, over-the-counter drugs, and nutritional supplements. Polypharmacy is known to increase the risk of adverse drugs reactions, drug-drug interactions, and medication errors, and to negatively impact quality of life. The prevalence of polypharmacy varies by population, but has been reported to exceed 90% among older adults with cancer. Polypharmacy may be exacerbated among older adults with cancer receiving radiation therapy due to the resulting acute or chronic side effects that need to be managed with additional medications. The medications prescribed to manage radiation-related side effects increase the risk of adverse drug events, as do changes in nutritional status related to the secondary side effects of radiation treatment. Side effects from treatment may result in the need for breaks in cancer therapy or treatment delays, which ultimately can lead to worse oncologic outcomes. Few studies have examined polypharmacy in the context of older adults undergoing radiation therapy. We sought to review the literature pertaining to polypharmacy among older adults with cancer and discuss implications specifically for those individuals undergoing radiation therapy. This paper presents a narrative review of studies published in the past decade that provided detailed information on polypharmacy in older adults undergoing radiation therapy for cancer. The review elucidated good practices to avoid adverse drug events from polypharmacy, but more studies are warranted to develop standard guidelines.
同时使用多种药物(包括处方药、非处方药和营养补充剂)被定义为多重用药。多重用药会增加药物不良反应、药物相互作用和用药错误的风险,并降低生活质量。多重用药的发生率因人群而异,但据报道,癌症老年患者的多重用药发生率超过 90%。接受放射治疗的癌症老年患者可能会加重多重用药的情况,因为治疗会产生急性或慢性副作用,需要用额外的药物来治疗。用于管理放射相关副作用的药物会增加药物不良事件的风险,与放射治疗的继发副作用相关的营养状况变化也是如此。治疗的副作用可能导致癌症治疗中断或治疗延迟,最终导致肿瘤学结局恶化。很少有研究在接受放射治疗的老年患者中考察多重用药。我们试图综述与癌症老年患者的多重用药相关的文献,并特别讨论正在接受放射治疗的个体的具体影响。本文对过去十年中发表的研究进行了叙述性综述,这些研究提供了有关癌症老年患者接受放射治疗时的多重用药的详细信息。综述阐述了避免多重用药引起药物不良反应的良好做法,但需要开展更多研究来制定标准指南。